App-Quantinova.ai

Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma

Gael Tavernier - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Addison's disease

Mepolizumab

Mepolizumab self-administration via autoinjector and prefilled syringe: the qualitative patient experience

Lee Evitt - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Mepolizumab

A patient’s perspective: The use of Oxygen Alert Wrist Bands (OxyBands) in COPD

Emma Rickards - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Oral corticosteroid prescription patterns in asthma care in Italy

Trung Tran - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

SABA and ICS use among mild asthma patients in UK primary care

Chloe Bloom - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Beclomethasone dipropionate

The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time

David A Lipson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Efficacy and safety of Mepolizumab in a real world severe asthma cohort

Verity Mitchell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial

Franois Maltais - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Umeclidinium

Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma

David Jackson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Glucocorticoid

Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care

Konstantinos Kostikas - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial

Paul Jones - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Umeclidinium

Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects

Alex Mulvanny - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis

Brian Kent - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Eosinophilic granulomatosis with polyangiitis

Prednisolone

The anti-IL-13 biologic tralokinumab did not alter expression of T2 and T17 transcription factors GATA3 and RORyT in bronchial biopsies

Latifa Chachi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

CAT-354

Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma

Latifa Chachi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study

Walter Giorgio Canonica - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment

John W. Upham - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Benralizumab

Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra

Ingmar Bruns - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Late Breaking Abstract - Identifying and addressing patient beliefs driving SABA use and over-reliance

Rob Horne - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

ICS/LABA effects on antiviral innate immune response. An in vitro analysis

Andrea Marcellini - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

Budesonide

Filters

45280 Abstracts